VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$3.07 USD
+0.11 (3.72%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $3.32 +0.25 (8.14%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 36% (91 out of 252)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.52 | 9.99 |
Current Quarter Estimate | -0.24 | -2.04 | 59.00 |
Year Ago Quarter Estimate | -1.74 | -0.59 | 50.37 |
Next Quarter Estimate | -0.25 | -2.00 | 60.00 |
Next Year Estimate | -0.96 | 6.92 | 250.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 63.24 | 8.20 | 26.94 |
Next Year | 4.00 | 13.90 | 8.00 |
Last 5 Years | NA | 7.20 | 9.00 |
Next 5 Years | NA | 23.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 0.48 | 1.80 |
Price/Cash Flow (MRFY) | NA | 8.48 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -6,710.38% | -53.08% |
Return on Equity (TTM) | -77.46% | -46.37% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.